secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001753926-24-001531
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical reports 82% sham-adjusted liver fat reduction with GLP-1 implant
-------------------------------------------------------------------------------

- Sham-implant adjusted liver fat reduction of 82% in obese mouse model from single administration with twice-yearly dosing.
- Previously reported 20% sham-implant adjusted weight loss, comparable to semaglutide arm.
- Clinical development for NPM-115 program (exenatide implant) in overweight/obese patients on track for Q4 2024 start in Australia.
- LIBERATE-1 first-in-human study expected to start Q4 2024 with data in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001531/0001753926-24-001531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001531/vani-20240904.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer